Wells Fargo & Company Mersana Therapeutics, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 48,115 shares of MRSN stock, worth $72,172. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,115

Previous 47,270 1.79%

Holding current value

$72,172

Previous $95,000 5.26%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.23 - $2.25 $1,039 - $1,901	845 Added 1.79%	48,115 $90,000
Q2 2024 Aug 13, 2024	BUY	$2.0 - $4.45 $19,290 - $42,920	9,645 Added 25.63%	47,270 $95,000
Q1 2024 May 10, 2024	BUY	$2.16 - $5.94 $14,675 - $40,356	6,794 Added 22.04%	37,625 $168,000
Q4 2023 Feb 09, 2024	BUY	$1.11 - $2.34 $8,664 - $18,266	7,806 Added 33.9%	30,831 $71,000
Q3 2023 Nov 13, 2023	SELL	$1.06 - $3.91 $84,670 - $312,322	-79,878 Reduced 77.62%	23,025 $29,000
Q2 2023 Aug 15, 2023	BUY	$3.08 - $9.55 $17,334 - $53,747	5,628 Added 5.79%	102,903 $338,000
Q1 2023 May 12, 2023	BUY	$4.0 - $7.02 $389,100 - $682,870	97,275 New	97,275 $399,000
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $1,958 - $3,384	423 Added 37.17%	1,561 $10,000
Q2 2022 Aug 12, 2022	SELL	$2.84 - $5.0 $47,132 - $82,980	-16,596 Reduced 93.58%	1,138 $5,000
Q1 2022 May 16, 2022	SELL	$3.74 - $6.63 $89,789 - $159,173	-24,008 Reduced 57.52%	17,734 $71,000
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $199,373 - $358,726	36,382 Added 678.77%	41,742 $259,000
Q3 2021 Nov 15, 2021	BUY	$8.56 - $14.47 $45,436 - $76,806	5,308 Added 10207.69%	5,360 $50,000
Q2 2021 Aug 16, 2021	SELL	$13.28 - $18.07 $282,797 - $384,800	-21,295 Reduced 99.76%	52 $1,000
Q1 2021 May 13, 2021	SELL	$15.31 - $26.52 $1.56 Million - $2.7 Million	-101,701 Reduced 82.65%	21,347 $345,000
Q4 2020 Feb 09, 2021	SELL	$16.84 - $27.59 $103,094 - $168,905	-6,122 Reduced 4.74%	123,048 $3.28 Million
Q3 2020 Nov 05, 2020	BUY	$16.2 - $25.7 $176,288 - $279,667	10,882 Added 9.2%	129,170 $2.41 Million
Q2 2020 Aug 13, 2020	BUY	$5.24 - $23.4 $219,314 - $979,383	41,854 Added 54.76%	118,288 $2.77 Million
Q1 2020 May 14, 2020	BUY	$4.41 - $9.28 $337,073 - $709,307	76,434 New	76,434 $446,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $146M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Mersana Therapeutics, Inc. Transaction History